MoonLake Immunotherapeuti Other Current Assets Over Time
| MLTX Stock | USD 42.37 1.64 4.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out MoonLake Immunotherapeuti Performance and MoonLake Immunotherapeuti Correlation. MoonLake |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MoonLake Immunotherapeuti. If investors know MoonLake will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MoonLake Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of MoonLake Immunotherapeuti is measured differently than its book value, which is the value of MoonLake that is recorded on the company's balance sheet. Investors also form their own opinion of MoonLake Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is MoonLake Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MoonLake Immunotherapeuti's market value can be influenced by many factors that don't directly affect MoonLake Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MoonLake Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if MoonLake Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MoonLake Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Current Assets Analysis
Compare MoonLake Immunotherapeuti and related stocks such as Terns Pharmaceuticals, Day One Biopharmaceu, and Acumen Pharmaceuticals Other Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 162 K | 461 K | 3.3 M | 1.9 M | 2.1 M | 4 M | 4.6 M | 4.8 M |
| DAWN | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 7 K | 1.3 M | 5.1 M | 5.6 M | 8.9 M | 4.4 M | 4.6 M |
| ABOS | 547 K | 547 K | 547 K | 547 K | 547 K | 547 K | 547 K | 547 K | 547 K | 547 K | 543 K | 4.4 M | 2.7 M | 2.9 M | 3.3 M | 2.4 M |
| AVTE | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 7 M | 2.3 M | 1.8 M | 2.1 M | 3.1 M |
| ELVN | 552 K | 552 K | 552 K | 552 K | 552 K | 552 K | 552 K | 552 K | 323 K | 1.7 M | 222 K | 646 K | 2.2 M | 13 M | 15 M | 15.7 M |
| GPCR | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 974 K | 1.9 M | 2.2 M | 6.3 M | 7.2 M | 7.6 M |
| CMPX | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 935 K | 3.1 M | 2.6 M | 8.2 M | 1.4 M | 1.6 M | 3.2 M |
| VTYX | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 1000 | 4.4 M | 12.7 M | 12.1 M | 13.9 M | 14.6 M |
| NUVL | 300 K | 300 K | 300 K | 300 K | 300 K | 300 K | 300 K | 300 K | 300 K | 300 K | 628 K | 5 M | 5.8 M | 6.6 M | 7.6 M | 4 M |
| TVTX | 21.8 K | 21.8 K | 21.8 K | 1.4 M | 813.4 K | 10.5 M | 8.3 M | 6 M | 4 M | 6.4 M | 8.1 M | 6.7 M | 15 M | 19.3 M | 12.7 M | 8.4 M |
| ACLX | 621 K | 621 K | 621 K | 621 K | 621 K | 621 K | 621 K | 621 K | 621 K | 621 K | 2.8 M | 8.2 M | 12 M | 14.3 M | 16.5 M | 8.3 M |
| AKRO | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 1.2 M | 1.6 M | 5.9 M | 10.6 M | 7.4 M | 10 M | 11.4 M | 5.8 M |
| ETNB | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 2 M | 5.6 M | 11.3 M | 15.8 M | 14.7 M | 16.9 M | 9.1 M |
| PLRX | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 1.7 M | 4.5 M | 6.8 M | 7.1 M | 8.3 M | 9.5 M | 5.3 M |
MoonLake Immunotherapeuti and related stocks such as Terns Pharmaceuticals, Day One Biopharmaceu, and Acumen Pharmaceuticals Other Current Assets description
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.My Equities
My Current Equities and Potential Positions
| MoonLake Immunotherapeutics | MLTX |
| Classification | Pharmaceutical Products |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 42.37
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.